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Summary: We describe an application of competitive reverse transcription-polymerase chain reaction (PCR) cou-
pled with HPLC for quantification of 2-adrenergic receptor messenger RNA (mRNA) in human atrial tissues
removed during cannulation for cardiopulmonary bypass operations. We constructed an internal standard which was
reverse transcribed in different concentrations together with constant levels of cellular RNA and subsequently PCR
amplified. The competitor RNA shows the same 2-adrenergic receptor primer sequences as the cellular mRNA but
yields a different-sized product. This allows resolution of the amplified copy DNA (complementary DNA, cDNA)
fragments with a specific HPLC column. The concentration of 2-adrenergic receptor mRNA is derived from the
ratio between the peak intensities corresponding to the amplified competitor and target products. We assessed the
imprecision, accuracy and sensitivity of the method. Concentrations of 2-adrenergic receptor mRNA of
22.7 ± 15.2 Χ 106 molecules pe^g total RNA in patients treated with 2-antagonists were not significantly dif-
ferent from control patients showing 16.8 ± 9.9 Χ 106 2-adrenergic receptor mRNA molecules per μg total RNA
(Mean ± SD). Competitive reverse transcription PCR is a highly specific, non-radioactive procedure for quantifica-
tion of 2-adrenergic receptor mRNA and simultaneously other gene expression levels of interest in atrial tissue
specimens and may therefore be used to advance our understanding of heart muscle disease.
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Although measurements of messenger RNA (mRNA) ducts only differ in their length, it can be assumed that
would be useful in advancing our understanding in hu- the reverse transcription PCR efficiencies are essentially
man heart disease, determinations of mRNA in human equal for 2-mRNA and the internal standard. In this
tissues have been limited to the large amount of myocar- procedure, the PCR aided transcript mration assaj'
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(PATTY) described by Becker-Andre & Hahlbrock (6),
identical portions of total cellular RNA are spiked with
increasing amounts of internal standard RNA. After re-
verse transcription, the resulting copy DNAs (cDNAs)
are amplified in a PCR assay where a competitive
primer annealing reaction between internal standard and
target sequence takes place. Within the linear range of
amplification, the doubling of the competitor cDNA cor-
responds to an approximate doubling of the target cDNA
for a given number of cycles.
Current techniques for detection and accurate quantifica-
tion of the small DNA fragments may be time-consum-
ing and hazardous. These procedures often use radiola-
belled nucleotides or primers and gel electrophoresis in
the presence of ethidium bromide (7, 8). Here we pre-
sent an alternative purification protocol using a compu-
terized HPLC device with ion exchange chromatography
(9) to separate each PCR product from free nucleotides
and excess primer. We also optimized the assay condi-
tions and determined the reliability of this reverse tran-
scription PCR/HPLC protocol to readily quantify ß2-
mRNA expression in minute clinical samples.
Materials and Methods
Subjects and tissue preparation
Two groups of 10 patients undergoing elective cardiac cardiopul-
monary bypass were recruited. All patients were clinically or chem-
ically euthyroid and none had severe ischemia. We selected patients
suffering from cardiac artery disease with heart failure (New York
Heart Association class) II-III and III.
One group of patients had been treated with -antagonists for at
least 3 months (nietoprolol 100 mg/d (n = 6), bisoprolol 5 mg/d
(n = 3), atenolol 50 mg/d (n = 1). The other group had not taken
ß-blockers for at least 3 months. None of the patients had received
calcium-antagonists, angiotensin converting enzyme inhibitors or
catecholamines.
In both groups, additional medication consisted of the cardiac gly-
coside digoxin (given to approximately half of the subjects) and
nitrates (given to approximately half of the subjects). Patients re-
ceived the medication up to the morning of surgery.
• r
The cardiac tissues (right heart auricle) were removed during can-
nulation for cardiopulrnonary bypass operations. Patients were nor-
mothermic at the time the tissue was removed. The heart tissues
were immediately frozen in liquid nitrogen and stored at —70 °C
until further processing.
Extraction of RNA
Total RNA was isolated by fractionated precipitation and anionic
exchange chromatography according to the manufacturer's proto-
col ("RNA-Isolationskit", Qiagen, Hilden, Germany; (10)). RNA
preparations were free from traces of remaining genomic DNA,
indicated by PCR without the reverse transcription step obtaining
no signal (negative control). The concentration of isolated RNA
was determined at 260 nm. The 260 nm : 280 run absorbance ratio
of the solution was found to be 1.8 to 2.0 which reveals high purity
of the RNA. Yields of RNA extraction varied between 8-17%.
Preparation of internal standard RNA
In reverse transcription PCR experiments for quantification of spe-
cific mRNA-species, one requires an internal standard RNA as
competitor. Therefore, we constructed a plasmid containing spe-
cific primer annealing sites identical to the target annealing sites.
In vitro transcription of this sequence provides the competitor RNA
for quantitative reverse transcription PCR. For construction, we
purchased two single-stranded DNA-sequences which were com-
plementary in 29 nucleotides at their 3'-ends (fig. 1). They possess
specific primer annealing sites for PCR-amplification of atrial na-
5'-Atrial natriuretic peptide-primer S'-ßpAdrenoceptor-primer 5'-ß2-Adreno-















Fig. 1 Construction of the internal standard DNA.
Two single stranded DNA-sequences, complementary in 29 bases
at their 3'-end were PCR-amplified by use of the 5'-atrial natriuretic
peptide primer and the 3'-ß-actin primer as described in "Materials
and Methods". The primer annealing sites are framed, the two for
the ß2-adrenoeeptor primers are shaded.
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triuretic peptide (ANP), radrenoceptor, 2-adrenoceptor, 3-adre-
noceptor and -actin sequences. In addition, the 51- and S'-primer
annealing sequences are separated by two single restriction sites
(Bell and XJwl). These DNA-sequences (0.1 nmol of each) were
treated in buffer containing 2mmol/l MgCl2/50 mmol/1 KC1/10
mmol/i Tris-Cl, pH 8.3/0.2 μπκ>!/1 dNTPs/10 units Taq polymerase
and incubated for 5 min at 95 °C (denaturation), 3 min at 64 °C
(annealing) and 30 min at 72 °C for synthesizing the double-
stranded DNA-sequence.
Using the outer primer-sequences (5'-atrial natriuretic peptide primer
and 3- -actin primer) PCR was performed, producing an amplifica-
tion product of 214 base pairs in length. The composition of the
assay and the reaction conditions were as follows: 2 mmol/1 MgCl2/
50 mmol/1 KC1/10 mmol/1 Tris-Cl, pH 8.3/0.2 μιηοΐ/ΐ dNTPs/5 U
Taq polymerase/2 ng double-stranded standard DNA and 50 pmol
of 5'-atrial natriuretic peptide primer and 3'- -actin primer. After a
denaturation step at 95 °C for 5 min, 15 cycles of 95 °C/1 min,
50 °C/1 min, 72 °C/1 min were performed followed by 20 cycles of
95 °C/1 min, 40 °C/1 min, 72 °C/1 min with a finishing elongation
step at 72 °C for 5 min. The resulting PCR-product (214 base pairs)
was cloned into the single Smal restriction site of the plasmid
pGEM-4Z (Promega, Madison, WI, USA) containing the SP6/T7
RNA promoter sequence. RNA transcripts of this internal standard
sequence were prepared as run-off transcripts by linearization at the
EcoRl site located just 3' to the standard sequence. In vitro transcrip-
tion was performed using a commercially available kit (Riboprobe
Gemini System II; Promega, Madison, WI, USA). Subsequently the
DNA-tempIate was digested by adding 10 units DNAse I
(FPLCpure, Pharmacia, Freiburg, Germany) to the reaction mixture
and incubating for 20 min at 37 °C. After ethanol precipitation, the
amount of internal standard RNA was determined at 260 nm. Ab-
sence of contaminating traces of remaining DNA template interfer-
ing in the competitive reverse transcription PCR assay was verified
by subjection of the RNA to a PCR without reverse transcription
obtaining no signal (negative control).
Competitive reverse transcription polymerase chain
reaction
cDNA synthesis was carried out in three different 20 μΐ reverse
transcription reactions each containing 200 ng of total RNA and
various amounts of the corresponding internal standard RNA (0.3
pg, 3 pg, 30 pg). RNA was reverse transcribed in a buffer contain-
ing 5mmol/l MgCI2/50 mmol/1 KC1/10 mmol/1 Tris-Cl, pH 8.3/
1 mmol/1 dNTPs/2.5 μπιοΐ/ΐ random hexamers/20 units of RNase
inhibitor and 100 units of reverse transcriptase: The reaction was
carried out at 42 °C for 20 min. Thereafter the mixture was incu-
bated at 99 °C for 5 min to inactivate enzymatic activity. PCR was
performed at final concentrations of 2 mmol/1 MgCl2/50 mmol/1
KC1/10 mmol/1 Tris-Cl, pH 8.3/0.2 mmol/1 dNTPs/1.25 units of
Taq polymerase and 12.5 pmol 2-adrenoceptor primers in a total
volume of 50 μΐ. Six μΐ of cDNA was added and PCR was per-
formed with 30 cycles of denaturation at 94 °C for l min, primer
annealing at 62 °C for l min and chain extension at 72 °C for
l min. All reverse transcription PCR additives were purchased
from Perkin Elmer ("GeneAmp® RNA PCR KIT", Perkin Elmer,
Uberlingen, Germany).
Amplification products were 397 base pairs in length for the target
RNA and 135 base pairs for the internal standard RNA.
High performance liquid chromatography
The products of the PCR reaction having different sizes were sepa-
rated from nucleotides, primers and amplified primer dimers on a
prepacked column with DEAE-bonded nonporous resin particles
of 2.5 μιη diameter (DEAE-NPR; no. N930-2656 from Perkin-El-
mer). The HPLC device was a Waters LCM1 plus system con-
sisting of two pumps 444, an automated gradient controller, an
autosampler 712, a UV detector 486 and a data module 746 for
registration and data analysis. Twenty to 80 μΐ from each PCR re-
action (1:5 diluted with water) were injected into the column and
the elution profile was registrated at 260 nm. The mobile phase
consisted of various volume proportions of buffer A (25 mmol/1
Tris-HCl, pH 9.0, plus 1 mol/1 NaCl) and buffer Β (25 mmol/1 Tris-
HC1, pH 9.0) in the following gradient program: 0.01 min, 46/54
(A/B); 0.50 min, 54/46; 8.00 min, 64/36; 10.00-12.00 min 46/54
to recalibrate the column. The total flow rate was 1 ml/min. The
data module of the HPLC device translated the amount of PCR
product into an area under the curve.
Quantif icat ion of 2-adrenoceptor mRNA
Regression analysis of the integrated peak areas corresponding to
the two specific PCR-products versus the amount of standard RNA
used in a semi-logarithmic diagram, leads to the point of equiva-
lence where the initial amount of target and standard RNA are the
same (fig. 2). This point of equivalence represents the equimolar
ratio of molecules of target and standard RNA initially present in
the assay. Therefore the value obtained must be corrected for the
different lengths of the PCR-fragments. For our 2-adrenoceptor













Internal Standard RNA [pgj
1000
Fig. 2 Competitive reverse transcription PCR for quantification
of 2-adrenoceptor mRNA.
Two-hundred ng of total RNA was subjected to reverse transcrip-
tion PCR together with 0.3 pg, 3 pg and 30 pg internal standard
RNA, respectively. The resulting peak areas after HPLC-detection
at 260 nm were plotted versus the amount of standard RNA used
in the assay (semi-logarithmic). The intersection (arrow) shows the
concentration of internal standard RNA used in the assay where
equimolar amounts of the products arise.
D 2-adrenoceptor, o Internal standard.
Results
Exponential PCR amplification of 2-adreno-
ceptor mRNA
To determine the exponential range of PCR amplification
for 2-adrenergic receptor mRNA and internal standard
RNA, we coreverse-transcribed 400 ng of total cellular
RNA isolated from heart tissue and 0.3 pg of internal stan-
dard RNA into the first-strand cDNAs. The cDNA pro-
ducts were then amplified for various numbers of cycles of
PCR. PCR products were size-fractionated through anionic
exchange HPLC, detected at 260 nm and the peak areas
corresponding to the two PCR-products were integrated.
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Fig. 3 Exponential range of amplification for 400 ng total cellular
RNA and 0.3 pg of internal standard RNA.
Cellular and internal standard RNA were coreverse-transcribed.
PCR of the cDNAs was performed for various numbers of cycles.
The integrated peak areas are plotted on the y-axis.
D 2-adrenoceptor, o internal standard.
Figure 3 shows the results obtained from the exponential
range experiment. Both the internal standard and the target
cDNAs were amplified in an exponential fashion from 24
to 36 cycles. The relative amounts of the two amplified
products stayed identical during the PCR amplification,
even when the plateau phase was reached.
For exact quantification results in determination of pa-
tients' heart tissue RNA, we had to show that the in-
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Fig. 4 Efficiencies of PCR-amplification for target- and stan-
dard-RNA.
Four-hundred ng total cellular RNA and 0.3 pg internal standard
RNA were reverse transcribed and subjected to 30 cycles of PCR.
Three different concentrations of the cDNA were used in the ampli-
fication reaction. The amplification rates are shown to be almost
the same.
D 2-adrenoceptor, o internal standard.
ilar efficiencies in the PCR. Therefore 0.3 pg internal
standard RNA and 400 ng total cellular RNA were re-
verse transcribed and subjected to 30 cycles of PCR (ex-
ponential range). Three different concentrations of the
cDNA (6 μΐ concentrated, 6 μΐ 1:2, 6 μΐ 1:4) were
used in the amplification reaction. Figure 4 shows that
amplification rates of internal standard RNA and target
RNA are almost the same. The parallelity of the lines
demonstrates that the proportion of both cDNAs does
not change during PCR.
HPLC analysis of PCR products
PCR products were separated from the various deoxy-
nucleotides, primers, amplified primer-dimers and non-
specific products by employing an elution gradient opti-
mized to separate DNA fragments in the range of 100
to 500 base pairs, that requires only 12 minutes cycle
time per sample. The presence of two single peaks of
PCR products with the expected size after HPLC analy-
ses (after calibration with a DNA marker) demonstrated
that none of our cDNAs had been contaminated with
genomic DNA during the RNA extraction procedure.
Assay evaluation
Linearity
The following assay was performed to evaluate the lin-
earity between the amount of initial cellular 2-adreno-
ceptor mRNA and the PCR product obtained after 30
j
'S
ι 9 18 100
Internal standard RNA [pg]
Fig. 5 Linearity of competitive reverse transcription PCR.
Two different amounts of the same cellular RNA (280 ng and 360
ng) were probed in a common competitive reverse transcription
PCR assay for 2-adrenoceptor mRNA (0.3 pg, 3 pg, 30 pg internal
standard RNA). For 180 ng total cellular RNA we determined the
intersection at 9 pg internal standard RNA and for 360 ng we found
the point of equivalence at 18 pg internal standard RNA.
B 2-adrenoceptor (180 ng), ο internal standard (180 ng), D 2-
adrenoceptor (360 ng), ο internal standard (360 ng).
Höhnel et al.: Measurement of ß2-receptor messenger RNA in the human heart 415
cycles of amplification. We probed two different
amounts of the same cellular RNA in a common com-
petitive reverse transcription PCR assay. Hundred and
eighty ng and 360 ng of total RNA were both subjected
to reverse transcription PCR, together with 0.3 pg, 3 pg
and 30 pg ß2-adrenoceptor internal standard RNA. Eval-
uation of the data reveals a linear response. For 180 ng
total cellular RNA, we determined the point of equiva-
lence at 9 pg internal standard RNA and 360 ng total
cellular RNA at 18 pg internal standard RNA (fig. 5).
Reliability ofHPLC analysis
To evaluate internal variations of HPLC analysis, we
subjected different amounts of the ß2-adrenoceptor PCR
product to repeated HPLC analyses. In table 1, the area
under the curve values of these experiments are shown.
For a relatively constant standard deviation of about
2400, corresponding to the internal variation due to the
baseline of the elution curve, the CV for the analysis
clearly depends on the size of the area under the curve.
Thus, to obtain an area under the curve with optimal
Tab. 1 Variation of HPLC analysis (area under the curve, arb.
































reproducibility, or a low CV in this study, we used input
cDNA volumes that would lead to PCR signals with an
area under the curve > 30 000.
Reproducibility
We calculated the CV of competitive reverse transcrip-
tion PCR by six replicate analyses of one sample (pa-
tient 2). The values.varied from 12.7 to 19.3 6 2-
adrenoceptor molecules (12.7, 14.5, 15.8, 17.2, 18.0,
19.3) with a mean of 16.3 106 ß2-adrenoceptor mole-
cules and a CV of 15%. These variations take into ac-
count variations associated with cDNA synthesis, PCR
amplification and HPLC analysis.
Accuracy and sensitivity
To test the accuracy of the method, we diluted total cellu-
lar RNA of one heart tissue preparation (patient 2, 16.3
106 ß2-adrenoceptor molecules per g total RNA) to
get 6 different concentrations. The samples were sub-
jected to reverse transcription PCR and analyzed as de-
scribed. The experimental values plotted against the ex-
pected ones (fig. 6) showed the ability of competitive re-
verse transcription PCR to discriminate between different
levels of ß2-adrenoceptor gene expression.
In repeated experiments, the sensitivity of the method
was determined as 0.9 106 ß2-adrenoceptor molecules
per g total RNA.
Quant i f icat ion of ß2-adrenoceptor mRNA
For quantification of specific mRNAs, total cellular
RNA of patient's heart tissues has to be isolated and
15 20
ß2-Adrenoceptor expected
[10* molecules per g total RNA)
Fig. 6 Accuracy and sensitivity of competitive reverse transcription PCR,
Total cellular RNA of one tissue preparation was diluted to 6 concentrations. Competitive
reverse transcription PCR was performed, evaluated and the experimental values were
plotted against the expected ones.
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purified. Using the method of fractionated precipitation
and anionic exchange chromatography we reached a
yield of up to 50 g RNA by preparation of approxi-
mately 170 mg human heart tissue. This in enough RNA
for performing more than 50 quantification assays of ß2-
adrenoceptor mRNA.
ß2-Adrenoceptor mRNA determination revealed that the
mean value of the control group (15.6 X 106 ß2-adreno-
ceptor mRNA molecules per g total RNA, tab. 2) is not
statistically significantly different from the mean value
of the group with -blocker medication (22.7 6 ß2-
adrenoceptor mRNA molecules per g total RNA,
Mann-Wiflmey-test, p < 0.5). The mean values are in
good agreement with data from Ladenson et al. (11)
and Bristow et al. (8) investigating the endomyocardium
and the left ventricular tissue, respectively. They give
values of 15 106 determined in a patient with dilated
cardiomyopathy and 22 mg ± 20 X 106 molecules ß2-
adrenoceptor mRNA per g total RNA in 12 patients
with non-failing heart disease. Strikingly, our data show
a high interindividual variability between the ß2-mRNA
expression levels in the investigated patient groups also
reported by Bristow et al. (8).
Tab. 2 p2-Adrenoceptor mRNA quantification results of all



























































Using the approach originally described by Becker-An-
dre & Hahlbrock (6), we have developed a new assay
for the quantification of ß2-adrenoceptor mRNA expres-
sion by PCR. The synthetic ß2-adrenoceptor RNA, de-
signed as an internal standard for this assay, controls the
efficiency of both the reverse transcription reaction and
the PCR. The synthetic RNA has the same primer se-
quences as the target mRNA, so that there are no differ-
ences in primer efficiencies. The difference in size be-
tween standard and target allows a simple and quick
separation of the corresponding amplification products
with anion-exchange HPLC.
Further, the constructed internal standard may also be
used for quantification of atrial natriuretic peptide ß l 9
ß3- and actin mRNA, respectively. The results of PCR-
based measurements of ß2-adrenoceptor mRNA in atrial
tissues from patients with cardiac artery disease show a
good correlation with studies in left ventricle myocar-
dium tissues from patients with non-failing human
heart (8).
The precision of the present non-radioactive assay is en-
hanced by the accurate measurement of the target and
competitor mRNA using anion-exchange HPLC for sep-
aration and quantification. We obtained a dose-depen-
dent linear response by using a constant amount of
cellular RNA and increasing concentrations of competi-
tor. These results demonstrate that the two cDNA spe-
cies are equivalent in the relative efficiency of amplifi-
cation. Imprecision for quantitative PCR assays with CV
lower than 15% in this and other studies (12) were re-
ported only for the PATTY procedure. Standardization
against the housekeeping gene ß-actin resulted in im-
precision lower than 25% (13), whereas traditional
methods of quantative PCR reported CVs as high as
40% (14, 15).
All the PCR experiments presented here were carried
out with the same stocks of primers and internal stan-
dard mRNA. Indeed, we observed that PCR results
could vary as much as 3-fold when we used different
stocks of internal standard RNA, synthesized at a dif-
ferent time. Even higher variations with a 10-fold differ-
ence in amplification yields were reported when dif-
ferent stocks of primers were used (13). We speculate
that the purity of the synthesized RNA might vary from
lot to lot, although there was only one single band on
the control gel electrophoresis.
HPLC has already been employed successfully for very
precise PCR product quantification over a wide dynamic
range of amplified DNA (9, 13, 16), possibly more pre-
cisely than it can be done by gel imaging or microplate-
based techniques. While a single PCR product analysis
is much faster by HPLC than by ethidium bromide-
stained gel electrophoresis, multiple analysis may re-
quire more time, since only one sample can be assayed
per run. As the resolution of the DEAE-NPR column
permits linear gradients of only 12 minutes per run, this
enables overnight analysis with the autosampler 712 of
up to 48 samples.
In conclusion, the enhanced ß2-adrenoceptor sensitivity
after ß!-blocker treatment remains unclear. The un-
changed ß2-adrenoceptor mRNA expression in this
study suggests that the relationship of steady state abun-
dance of ß2-adrenoceptor mRNA and ß2-receptor pro-
tein levels in model systems (17, 18) may also exist in
the human heart. The ability to measure steady-state
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levels of cardiac mKNA provides a new approach to
understanding the molecular and cellular mechanisms
that contribute to myocardial disease.
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